BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance. Despite that several target-based approaches with potential therapeutic impact on SCLC have been identified, numerous targeted drugs have not been succe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentino, Francesco Paolo, Marchesi, Irene, Schröder, Christoph, Schmidt, Ronny, Yokota, Jun, Bagella, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766292/
https://www.ncbi.nlm.nih.gov/pubmed/33339368
http://dx.doi.org/10.3390/ijms21249595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766292/
https://www.ncbi.nlm.nih.gov/pubmed/33339368
http://dx.doi.org/10.3390/ijms21249595

Ejemplares similares